‹ BCRX latest research

BCRX (BioCryst Pharmaceuticals, Inc.): every AI call and what happened next

TradeFlare's AI research teams analysed BCRX on 10 market nights between April 21, 2026 and July 16, 2026. Each row is that night's verdict, the price that day, and how the price actually moved afterwards — wins and misses alike. Nothing is edited after the fact.

10 calls 8 BUY · 2 HOLD · 0 SELL BUY calls up after 20 trading days: 2 of 8
DateVerdictPriceTarget / stop5 days later20 days laterWhy (that night)
July 16, 2026 BUY $9.41 $11.29 / $8.00 +3.0% +7.7%
The combination of oversold technicals, strong fundamental and sentiment backing, and a clear catalyst window suggests a multi-week recovery potential.
July 8, 2026 BUY $10.99 $13.19 / $9.34 -15.3% -18.4%
The 52-week breakout suggests potential for continued momentum over a few weeks.
May 12, 2026 HOLD $8.58 — / — -0.3% -6.9%
Continued strong performance and market adoption of ORLADEYO.
May 11, 2026 BUY $8.62 — / — +4.5% -2.9%
Continued strong commercialization and market adoption of ORLADEYO.
April 28, 2026 BUY $8.90 — / — +1.9% +2.9%
The current market conditions and technical indicators suggest a period of consolidation is needed before a clear trading opportunity emerges.
April 27, 2026 BUY $8.94 — / — +3.4% -4.8%
Continued positive performance and market penetration of Orladeyo.
April 24, 2026 BUY $8.76 — / — +2.8% -7.3%
The current market regime and technicals suggest a cautious approach, waiting for a clearer catalyst.
April 23, 2026 BUY $9.01 — / — +4.6% -4.5%
Continued strong performance and market penetration of ORLADEYO®.
April 22, 2026 BUY $8.58 — / — -0.2% -3.0%
Continued strong performance and positive guidance for ORLADEYO.
April 21, 2026 HOLD $9.19 — / — +3.3% +2.2%

Prices are daily closes. "Days later" counts trading days from the close on the day of the call. A HOLD is not a recommendation to buy; only published signals are tracked with a target and stop on the public record. How the research works. Updated October 14, 2026. AI-generated research for educational purposes — it can be wrong and is not financial advice.